Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00773357 · ClinicalTrials.gov registry record · Phase 2
Modeling Stress-precipitated Smoking Behavior for Medication Development
A Phase 2 study of Smoking, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00773357 is a Phase 2 study of Smoking that has completed, run by Yale University. The registered enrollment target is 100 participants, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00773357, a Phase 2 study of Smoking, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine whether guanfacine will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking and non-treatment seeking daily smokers.
Conditions Studied
Interventions
- DRUG placebo
- DRUG guanfacine
Study Locations (1)
Connecticut
- Yale Center for Clinical Investigation, Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-10 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00773357
The ClinicalTrials.gov registry entry for NCT00773357 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (78% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00773357 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00773357 about?
NCT00773357 is a clinical study titled "Modeling Stress-precipitated Smoking Behavior for Medication Development". The purpose of this study is to examine whether guanfacine will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking and non-treatment seeking daily smokers.
What is the current status of trial NCT00773357?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2008-10. Estimated completion is 2021-07-31.
What conditions does trial NCT00773357 study?
This clinical trial studies the following conditions: Smoking.
What interventions are being tested in trial NCT00773357?
The interventions under investigation include: placebo (DRUG), guanfacine (DRUG).
Who is sponsoring clinical trial NCT00773357?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00773357 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence
RECRUITING · Phase 2
-
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
RECRUITING · Phase 2
-
App for Reducing Cravings to Smoke
RECRUITING · Phase 2
-
Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava
ACTIVE NOT RECRUITING · Phase 2
-
Proactive Health Intervention for Tobacco Users (Get PHIT)
COMPLETED · Phase 2
-
Computer-Assisted Intervention for Smoking During Pregnancy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.